It’s considered a scientific landmark: A 1975 meeting at the Asilomar Conference Center in Pacific Grove, California, shaped a new safety regime for recombinant DNA, ensuring that researchers would apply caution to gene splicing. Those ideas have been so useful that in the decades since, when new topics in scientific safety arise, there are still calls for Asilomar-type conferences to craft good ground rules. There’s something missing from this narrative, though: It took more than the Asilomar conference to set today’s standards. The Asilomar concepts were created with academic research in mind — but the biotechnology industry also makes products, and standards for that were formulated after Asilomar. “The Asilomar meeting and Asilomar principles did not settle the question of the safety of genetic engineering,” says MIT scholar Robin Scheffler, author of a newly published research paper on the subject. Instead, as Scheffler documents in the paper, Asilomar helped generate further debate, but those industry principles were set down later in the 1970s — first in Cambridge, Massachusetts, where politicians and concerned citizens wanted local biotech firms to be good neighbors.

Full history : MIT historian Robin Scheffler’s research shows how local regulations helped create certainty and safety principles that enabled an industry’s massive growth.